Erratum: Daiichi Sankyo US approval for Effient

In the electronic-only story titled Japan stock market week to April 6, 2009, the item describing the share activity of Daiichi Sankyo said that  its "management expects" the anti-platelet drug prasugrel (to be  marketed in the USA as Effient) to gain US approval possibly "by the end  of April." The Marketletter's report was based on comments made at the  drugmaker's R&D presentation in Tokyo. However, Daiichi Sankyo's US  subsidiary has asked us to make clear that the company cannot speculate  on the timing or nature of the action that the US Food and Drug  Administration will take with the Effient New Drug Application.